The ABC for a TB Activist: 1/4/6×24 Campaign and Supportive Diagnostics
Webinars • 2023On 15 June, 2023, TB Europe Coalition (TBEC) organized a webinar featuring a presentation by Treatment Action Group’s TB Project Officer, David Branigan, on the practical actions advocates can take to promote the adoption and scale up of shorter, safer 1/4/6 regimens for TB prevention and the treatment of drug-sensitive and drug-resistant TB as well as supportive diagnostics.
Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%
Publication • 2023In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.
The 1/4/6×24 Campaign Coalition Welcomes India’s Rejection of Johnson & Johnson’s Patent Evergreening Tactic
Statement / Press • 2023The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.
Open Letter: Urgent Action Necessary to Improve Equitable Access to Bedaquiline-Based Regimens and Achieve 1/4/6×24
Letters • 2023TAG and a coalition of civil society activists, public health leaders, and researchers acting in solidarity with communities affected by tuberculosis sent an open letter to Johnson & Johnson calling on the company to publicly commit to withdraw and not enforce the fumarate salt patent claims and other secondary patents on bedaquiline, as part of…
Open Letter: Urgent action necessary to improve equitable access to GeneXpert tuberculosis diagnostics and achieve 1/4/6×24
Letters PDF • 2023TAG and a coalition of civil society activists, public health leaders, and researchers acting in solidarity with communities affected by tuberculosis sent an open letter to Cepheid calling on the company to take urgent action necessary to improve equitable access to GeneXpert tuberculosis diagnostics and achieve 1/4/6x24.
Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply
Letters • 2023TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.
Call for Expression of Interest: Community Advisory Boards to Support Community Engagement in Research under the SMART4TB Project
Page • 2023The SMART4TB Consortium is calling for expressions of interest from multi-national community advisory boards (CAB) or similarly organized civil society organizations within three geographic focus areas to support community engagement in research in a new five-year research project funded by USAID.CROI 2023 Tuberculosis Research Round Up
Statement / Press • 2023Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).
Treatment Action Group Announces Palm Desert Exhibition at Melissa Morgan Fine Art – “35 Years of Art to End AIDS”
Statement / Press • 2023Treatment Action Group (TAG) is pleased to present the exhibition “35 Years of Art to End AIDS” at Melissa Morgan Fine Art in Palm Desert, CA. The exhibition features selected works from TAG’s Limited Art Editions Collection and will run from March 17 through April 7.
TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands
Statement / Press • 2023After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...